Dana Kalabova

Dana Kalabova

Auto-generated profile, based on publicly available information

Dana Kalabova

Division BIOCEV, Department of Structural Biology of Signaling Proteins, Institute of Physiology of the Czech Academy of Sciences, Vestec, Czech Republic

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
KPKatarina Psenakova
Katarina Psenakova
OPOlivia Petrvalska
Olivia Petrvalska
SKSalome Kylarova
Salome Kylarova
DSDomenico Lentini Santo
Domenico Lentini Santo
DKDana Kalabova
Dana Kalabova
Tomas ObsilTomas Obsil
Tomas Obsil

21 January 2020 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
DKDana Kalabova
Dana Kalabova
FFFrantisek Filandr
Frantisek Filandr
MAMiroslava Alblova
Miroslava Alblova
OPOlivia Petrvalska
Olivia Petrvalska
MHMatej Horvath
Matej Horvath
VOVeronika Obšilová
Veronika Obšilová
Among all species, caspase‐2 (C2) is the most evolutionarily conserved caspase required for effective initiation of apoptosis following death stimuli. C2 is activated through dimerization and autoproteolytic cleavage and inhibited through phosphorylation at Ser139 and Ser164, within the linker between the caspase recruitment and p19 domains of the zymogen, followed by association with the adaptor protein 14‐3‐3, which maintains C2 in its immature form procaspase (proC2). However, the mechanism of 14‐3‐3‐dependent inhibition of C2 activation remains unclear. Here, we report the structural characterization of the complex between proC2 and 14‐3‐3 by hydrogen/deuterium mass spectrometry and protein crystallography to determine the molecular basis for 14‐3‐3‐mediated inhibition of C2 activation. Our data reveal that the 14‐3‐3 dimer interacts with proC2 not only through ligand‐binding grooves but also through other regions outside the central channel, thus explaining the isoform‐dependent specificity of 14‐3‐3 protein binding to proC2 and the substantially higher binding affinity of 14‐3‐3 protein to proC2 than to the doubly phosphorylated peptide. The formation of the complex between 14‐3‐3 protein and proC2 does not induce any large conformational change in proC2. Furthermore, 14‐3‐3 protein interacts with and masks both the nuclear localization sequence and the C‐terminal region of the p12 domain of proC2 through transient interactions in which both the p19 and p12 domains of proC2 are not firmly docked onto the surface of 14‐3‐3. This masked region of p12 domain is involved in C2 dimerization. Therefore, 14‐3‐3 protein likely inhibits proC2 activation by blocking its dimerization surface.Databases: Structural data are available in the Protein Data Bank under the accession numbers 6SAD and 6S9K.

1 April 2003 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
DHD. Habart
D. Habart
DKD. Kalabova
D. Kalabova
MNM. Novotny
M. Novotny
ZVZ. Vorlova
Z. Vorlova

1 February 2004 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
CSChairat Shayakul
Chairat Shayakul
PJPetr Jarolim
Petr Jarolim
MZMarie Zachlederova
Marie Zachlederova
DPDaniel Prabakaran
Daniel Prabakaran
DCDionisio Cortez-Campeao
Dionisio Cortez-Campeao
SASeth L. Alper
Seth L. Alper
Mutations in the human SLC4A1 (AE1/band 3) gene are associated with hereditary spherocytic anaemia and with distal renal tubular acidosis (dRTA). The molecular diagnosis of AE1 mutations has been complicated by the absence of highly polymorphic genetic markers, and the pathogenic mechanisms of some dRTA-associated AE1 mutations remain unclear. Here, we characterized a polymorphic dinucleotide repeat close to the human AE1 gene and performed an immunocytochemical study of kidney tissue from a patient with inherited dRTA with a defined AE1 mutation. One CA repeat region was identified in a phage P1-derived artificial chromosome (PAC) clone containing most of the human AE1 gene and the upstream flanking region. We determined its heterozygosity value in multiple populations by PCR analysis. Genotyping of one family with dominant dRTA identified the AE1 R589H mutation, and family member genotypes were compared with the CA repeat length. AE1 and vH(+)-ATPase polypeptides in kidney tissue from an AE1 R589H patient were examined by immunocytochemistry for the first time. This CA repeat, previously reported as D17S1183, is approximately 90 kb upstream of the AE1 gene and displayed considerable length polymorphism, with small racial differences, and a heterozygosity value of 0.56. The allele-specific length of this repeat confirmed co-segregation of the AE1 R589H mutation with the disease phenotype in a family with dominant dRTA. Immunostaining of the kidney cortex from one affected member with superimposed chronic pyelonephritis revealed vH(+)-ATPase-positive intercalated cells in which AE1 was undetectable, and proximal tubular epithelial cells with apparently enhanced apical vH(+)-ATPase staining. The highly polymorphic dinucleotide repeat adjacent to the human AE1 gene may be useful for future studies of disease association and haplotype analysis. Intercalated cells persist in the end-stage kidney of a patient with familial autosomal dominant dRTA associated with the AE1 R589H mutation. The absence of detectable AE1 polypeptide in those intercalated cells supports the genetic prediction that the AE1 R589H mutation indeed causes dominant dRTA.

3 October 2018 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
ASAneta Smidova
Aneta Smidova
MAMiroslava Alblova
Miroslava Alblova
DKDana Kalabova
Dana Kalabova
KPKatarina Psenakova
Katarina Psenakova
MRMichal Rosulek
Michal Rosulek
VOVeronika Obšilová
Veronika Obšilová
Caspase‐2 is an apical protease responsible for the proteolysis of cellular substrates directly involved in mediating apoptotic signaling cascades. Caspase‐2 activation is inhibited by phosphorylation followed by binding to the scaffolding protein 14‐3‐3, which recognizes two phosphoserines located in the linker between the CARD and the p19 domains of the caspase‐2 zymogen. However, the structural details of this interaction and the exact role of 14‐3‐3 in the regulation of caspase‐2 activation remain unclear. Moreover, the caspase‐2 region with both 14‐3‐3 binding motifs also contains the nuclear localization sequence, thus suggesting that 14‐3‐3 binding may regulate the subcellular localization of caspase‐2. Here, we report a structural analysis of the 14‐3‐3ζ:caspase‐2 complex using a combined approach based on small angle X‐ray scattering, NMR, chemical crosslinking and fluorescence spectroscopy. The structural model proposed in this study suggests that phosphorylated caspase‐2 and 14‐3‐3ζ form a compact and rigid complex in which the p19 and the p12 domains of caspase‐2 are positioned within the central channel of the 14‐3‐3 dimer and stabilized through interactions with the C‐terminal helices of both 14‐3‐3ζ protomers. In this conformation, the surface of the p12 domain, which is involved in caspase‐2 activation by dimerization, is sterically occluded by the 14‐3‐3 dimer, thereby likely preventing caspase‐2 activation. In addition, 14‐3‐3 protein binding to caspase‐2 masks its nuclear localization sequence. Therefore, our results suggest that 14‐3‐3 protein binding to caspase‐2 may play a key role in regulating caspase‐2 activation.

1 November 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
DKDana Kalabova
Dana Kalabova
ASAneta Smidova
Aneta Smidova
OPOlivia Petrvalska
Olivia Petrvalska
MAMiroslava Alblova
Miroslava Alblova
DKDalibor Kosek
Dalibor Kosek
VOVeronika Obšilová
Veronika Obšilová